Abstract 284MO
Background
Bone marrow-derived macrophages account for a substantial Glioblastoma (GBM) tumor volume and contribute to the local inflammatory tumor microenvironment (TME), disease progression & treatment response.
Methods
We have developed a genetically modified, autologous hematopoietic stem cell-based platform designed to deliver IFNa, specifically into the TME via Tie-2 expressing monocytes (Temferon). TEM-GBM is an open-label, phase I/IIa dose-escalation study evaluating safety and efficacy of Temferon in up to 21 newly diagnosed, unmeth-MGMT GBM patients. The patients will be assigned to 7 cohorts and will receive a single increasing dose of Temferon.
Results
As of April 2022, 4 doses of Temferon (0.5-3.0x106/kg) were tested across 16 patients assigned to 6 cohorts. Follow-up from surgery is 6–28mo (2–25mo after Temferon). To date, no DLTs have been identified. Temferon-derived progeny as defined by gene-marked cells were found within the hematopoietic system within 2-weeks of Temferon administration and persisted, albeit at lower levels, up to 18mo (longest time of analysis). Very low concentrations of IFNα were detected in plasma and CSF, indicating tight regulation of transgene expression. SAEs were mostly attributed to conditioning chemotherapy (infections) or disease progression (PD) (seizures). 1SUSAR (persistent GGT elevation) occurred. Median OS is 15mo from surgery. Transduced cells were detected in the 2nd surgery specimens of 3 out 4 pts belonging to low dose cohorts. Single-cell RNA seq of the TME highlighted a Temferon signature associated with the induction IFNa responsive genes and macrophage repolarization. Potential long-term benefit with Temferon was identified in a patient from C3, who had PD at D+120 with 2-distant enhancing lesions, and increased tumor necrosis. 1y following Temferon, with no 2nd-line therapy added, there was approximately 40% reduction in enhancing tumor volume compared to D+180 with a stable clinical and imaging picture thereafter.
Conclusions
The results provide initial evidence of Temferon’s potential to modulate GBM TME, and anecdotal evidence for long lasting effects of Temferon in prevention of PD.
Clinical trial identification
NCT03866109.
Editorial acknowledgement
Legal entity responsible for the study
Genenta Science.
Funding
Genenta Science.
Disclosure
B. Gentner: Financial Interests, Personal, Stocks/Shares: Genenta Science; Financial Interests, Institutional, Research Grant: Genenta Science; Financial Interests, Personal, Advisory Role: Genenta Science. S. Mazzoleni: Financial Interests, Personal, Full or part-time Employment: Genenta Science. L. Naldini: Financial Interests, Personal, Stocks/Shares: Genenta Science; Financial Interests, Institutional, Research Grant: Genenta Science; Financial Interests, Personal, Advisory Role: Genenta Science. C. Russo: Financial Interests, Personal, Full or part-time Employment: Genenta Science; Financial Interests, Personal, Stocks/Shares: Genenta Science. All other authors have declared no conflicts of interest.
Resources from the same session
281MO - Quality of life and neurocognitive function in patients with active brain metastases of HER2-positive breast cancer treated with trastuzumab-deruxtecan: Secondary endpoint analysis of the prospective single-arm phase II TUXEDO-1 trial
Presenter: Angelika M. Starzer
Session: Mini Oral session: CNS tumours
Resources:
Abstract
Slides
Webcast
282MO - Brain metastases: Real-life treatment patterns, survival and patient-reported outcomes – Results from a population-based, prospective study in 914 patients
Presenter: Olav Yri
Session: Mini Oral session: CNS tumours
Resources:
Abstract
Slides
Webcast
283MO - Leptomeningeal disease (LMD) in patients (pts) with metastatic melanoma (MM): Survival analysis of a contemporary cohort
Presenter: Isabella Glitza
Session: Mini Oral session: CNS tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant 281MO, 282MO and 283MO
Presenter: Enrico Franceschi
Session: Mini Oral session: CNS tumours
Resources:
Slides
Webcast
285MO - The combination of lomustine and antibody-based targeted TNF (L19TNF) as a promising treatment for recurrent glioblastoma
Presenter: Tobias Weiss
Session: Mini Oral session: CNS tumours
Resources:
Abstract
Slides
Webcast
286MO - Radiomics-based prediction of lymphocyte infiltration in IDH-wildtype glioblastoma
Presenter: Maximilian Mair
Session: Mini Oral session: CNS tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant 284MO, 285MO and 286MO
Presenter: Monika Hegi
Session: Mini Oral session: CNS tumours
Resources:
Slides
Webcast
287MO - A phase 0 ‘trigger’ trial of pamiparib in newly diagnosed and recurrent glioblastoma patients
Presenter: Nader Sanai
Session: Mini Oral session: CNS tumours
Resources:
Abstract
Slides
Webcast
288MO - Brain-only oligometastatic cancer patients present with longer overall survival than patients with extracranial involvement
Presenter: Ariane Steindl
Session: Mini Oral session: CNS tumours
Resources:
Abstract
Slides
Webcast
289MO - Next-generation sequencing (NGS) for identifying actionable molecular alterations in newly diagnosed and recurrent IDHwt-glioblastoma (GBM) patients: A large mono institutional experience
Presenter: Marta Padovan
Session: Mini Oral session: CNS tumours
Resources:
Abstract
Slides
Webcast